Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with mycosis fungoides confirmed by a skin biopsy~* Stage I or IIA patients must have been treated previously with prior topical therapies including PUVA, UVB, topical steroids, but not NM within the past 2 years, or topical carmustine (BCNU)~* Patients must be otherwise healthy with acceptable organ function.~* Prior to initiating study therapy, patients must not have had topical therapy within four weeks~* Lab values within normal range~* Willing/able to give consent~* Must use effective means of contraception if of childbearing potential~Exclusion Criteria:~* Newly diagnosed mycosis fungoides with no prior therapy~* A prior history of treatment with topical NM within the past 2 years or topical carmustine (BCNU)~* Use of topical or systemic therapies for MF within four (4) weeks of entry in the study~* Patients with a diagnosis of stage IIB-IV MF~* Serious known concurrent medical illness or infection, which could potentially present a safety risk and/or prevent compliance with the requirements of the treatment program~* Pregnant or nursing females, or males and females of childbearing potential, not using an effective means of contraception~* Patients who have had radiation therapy within one year of study start~* Patients who have a history of a higher T score than T2 or a higher N score than N1~* Patients who do not agree to do all labs at one site

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (PG - NM (MCH) 0.02%) (Type: ACTIVE_COMPARATOR): PG - mechlorethamine-MCH (nitrogen mustard) 0.02% gel To evaluate the tolerability and safety of topical mechlorethamine-MCH (nitrogen mustard) 0.02% ointment formulations in patients with stage I or IIA MF
- 2 (AP - MCH(NM) 0.02%) (Type: ACTIVE_COMPARATOR): AP - mechlorethamine-MCH (nitrogen mustard) 0.02% compounded in Aquaphor To evaluate the tolerability and safety of mechlorethamine-MCH (nitrogen mustard)0.02% ointment formulations in patients with stage I or IIA MF

Based on this trial design, predict the completion outcome and termination type (if applicable).